+ Watch RGLS
on My Watchlist
Takeover candidate in which All-Stars have recently ended red thumbs. 70% insider and 4.6 Quick Ratio indicates a takeover is not a necessity here.
Personally, I'm far from convinced that Regulus has dropped back to an appropriate valuation for their unproven, early stage micro RNA pipeline. Nevertheless, my red thumb was out of sync with my real life #zzporte position of 1000 shares bought at 7.5. The stock peaked over 12 before the company raised 46M from a dilutive financing at 9.5, which seems to have been their best strategic move in their brief existence. Now there's not much to do except wait for the share price to settle and see if Regulus can follow in the steps of Alnylam, Arrowhead, and Tekmira to outperform despite a lack of late stage pipeline accomplishments.
Short. Biotech. High P/S ratio.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions